Immunophenotyping of acute leukemias and myelodysplastic syndromes

Órfão, Alberto; Ortuño, Francisco José; Santiago, M. de Jesús Gallegos; López, Antonio; Miguel, Jesús F. San

doi:10.1002/cyto.a.10104

Cited by 84 publications

(90 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…MFC was performed by applying 5-fold stainings and using the antibodies outlined in Table 1 (selected based on previous studies). [13][14][15]28,29 Antibodies were purchased from Immunotech (Marseilles, France) except for carcinoembryonic antigen-related cell adhesion molecule 6/nonspecific cross-reacting antigen (cluster of differentiation [CD] 66c [CD66c]) (Becton Dickinson, Heidelberg, Germany). Antibody combinations were added to 10 6 mononuclear cells (volume, 100 lL) and incubated for 10 minutes.…”

Section: Multiparameter Flow Cytometrymentioning

confidence: 99%

“…The percentage of blasts was calculated by using the total amount of mononuclear cells after sample preparation as the denominator. According to previous reports, [13][14][15]28,29 the following features were evaluated. Granulocytes were evaluated for SSC signal, abnormal alanine aminopeptidase (CD13)/human neutrophil antigen 1 (CD16) and integrin a M (CD11b)/CD16 expression patterns, neural cell adhesion molecule (CD56) coexpression, 67-kDa membrane glycoprotein (CD33) negativity, and integral membrane glycoprotein (CD64) negativity.…”

Section: Gating Strategymentioning

confidence: 99%

See 1 more Smart Citation

Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome

Kern¹,

Haferlach²,

Schnittger³

et al. 2010

Cancer

View full text Add to dashboard Cite

BACKGROUND:The diagnosis and classification of myelodysplastic syndromes (MDS) is based on cytomorphology (CM) and cytogenetics (CG). Multiparameter flow cytometry (MFC) may add important diagnostic information. METHODS: To evaluate the potential role of MFC in the diagnostic setting of MDS, the authors analyzed the results from 1013 patients with suspected MDS by using CM, CG, and MFC in parallel. RESULTS: Concordance between CM and MFC was 82% for diagnostic results in 788 patients who had unequivocal CM results. An additional 225 patients had only minor dysplastic features identified by CM, including 51 patients (22.7%) who had clear evidence of MDS by MFC. Twelve patients who had no indication of MDS identified by CM had MDS-typical CG aberrations; in 6 of those patients (50%), MFC revealed MDS characteristics. In another 11 of 23 patients (47.8%) who had minor dysplastic features identified by CM and MDS-typical CG aberrations, MFC revealed MDS characteristics. The percentages of blasts determined by CM and by MFC were strongly correlated (P < .001). The frequency of aberrantly expressed antigens differed significantly between patients rated by CM as MDS (highest frequencies), suspected MDS, and no MDS (lowest frequencies). In various patients, MFC identified MDS-typical aberrant antigen expression in cell compartments that were not rated dysplastic by CM. The numbers of aberrantly expressed antigens were correlated with International Prognostic Scoring System scores and overall survival. CONCLUSIONS: The current analysis clearly demonstrated an increased diagnostic yield with MFC when added to CM and CG in patients with suspected MDS. Cancer

show abstract

Section: Multiparameter Flow Cytometrymentioning

confidence: 99%

Section: Gating Strategymentioning

confidence: 99%

Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome

Kern¹,

Haferlach²,

Schnittger³

et al. 2010

Cancer

View full text Add to dashboard Cite

show abstract

“…3 and 4) were performed as previously described (15,16) and analyzed either in a FACScan or FACSCalibur flow cytometer with CellQuest software (BD Biosciences). The following mAbs were initially used for flow cytometry analysis of IREM-2 expression on freshly obtained or in vitro cultured PBMC: anti-HA, antimyc, anti-IREM-2 (UP-H1 and UP-H2) and PE-labeled IgG Abs against CD4, CD80, CD14, CD1a and isotype matched control Abs (Becton Dickinson).…”

Section: Immunophenotypic Studiesmentioning

confidence: 99%

Molecular Characterization of a Novel Immune Receptor Restricted to the Monocytic Lineage

Aguilar

Álvarez-Errico

García‐Montero

et al. 2004

The Journal of Immunology

Self Cite

View full text Add to dashboard Cite

Homology basic local alignment search tool search was conducted using a sequence encoding for a novel inhibitory receptor (IREM-1) cloned in our laboratory and a previously described homologous sequence termed CMRF-35. On the basis of this information, we cloned a full length cDNA corresponding to a novel member of this family, termed immune receptor expressed by myeloid cells 2 (IREM-2). The gene, located in chromosome 17q25.1, encodes for a protein of 205 aa that contains an extracellular region comprising an Ig-like domain and a transmembrane region with a positively charged amino acid residue (lysine), that predicted its putative association with an adapter molecule. Indeed, the interaction between IREM-2 and DAP-12 was confirmed in transfected COS-7 cells. By generating specific Abs and using bone marrow and PBMCs, we observed that IREM-2 expression appeared to be restricted to mature hemopoietic cells of the monocytic and myeloid dendritic cell lineages. In vitro differentiation to macrophages or immature dendritic cells down-regulated IREM-2 expression. Upon engagement with the specific mAbs, IREM-2 expressed in rat basophilic leukemia cells together with DAP-12, induced NFAT transcriptional activity; moreover, IREM-2 engagement on monocytes induced TNF-α production. Taken together, our results indicate that IREM-2 is a novel activating receptor of the Ig-superfamily in the monocytic lineage.

show abstract

“…Por otra parte, los casos con t(8;21) muestran frecuentemente expresión de CD19 y CD56, mientras que los casos con anomalías a nivel de 11q23 se asocian a fenotipo CD56+, 7.1-/+, CD2-/+ y CD19-/+ débil (16). Se recomendaron anticuerpos básicos para el diagnóstico y la clasificación de las leucemias mieloides agudas y el rastreo de alteraciones genéticas características de diferentes subtipos de la enfermedad (tabla 5).…”

Section: Paneles Inmunofenotípicos Para El Estudio De Leucemia Mielobunclassified

Reporte del Primer Consenso Colombiano de Citometría de Flujo para el estudio de trastornos hematológicos

et al. 2012

Self Cite

View full text Add to dashboard Cite

Immunophenotyping of acute leukemias and myelodysplastic syndromes

Cited by 84 publications

References 74 publications

Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome

Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome

Molecular Characterization of a Novel Immune Receptor Restricted to the Monocytic Lineage

Reporte del Primer Consenso Colombiano de Citometría de Flujo para el estudio de trastornos hematológicos

Contact Info

Product

Resources

About